DATATRAK Customer Confidence Strong

/EINPresswire.com/ -- CLEVELAND, OH--(Marketwired - February 03, 2016) -  DATATRAK International, Inc. (OTCQX: DTRK), the leader in developing cloud-based, unified dClinical™ technologies, today announced its participation in the FIRST NTT Data User Group meeting held in Tokyo, Japan.

"This meeting was necessitated by an ever growing number of trained users in the Japanese market. Over 50 customers were in attendance demonstrating the confidence they have in the DATATRAK ONE® Unified Platform," said Laurence P. Birch, CEO and President of DATATRAK. "We were gratified to hear our customers describe the perceived value of our product solution portfolio. EDC, CTMS and randomization were all enthusiastically discussed. Simplicity was named as the number one feature of the system. NTT customers using DATATRAK ONE® identified significant cost and time savings as a result of the single database architecture."

"Providing robust solutions to each NTT Data client ensures a good customer experience," reflected Tim Lyons, Vice President of Product Development and Operations. "Our product development process focuses on removing clinical trial complexities. Moreover our team works closely with NTT Data and their customers to identify ways to simplify the drug and device development data capture process." Lyons concluded, "Our Platform is so robust this gave NTT Data and DATATRAK the opportunity to share the many attributes of the system unknown to even the most frequent users while also gaining great insights as to future enhancements that we will schedule for future release.

"We know customers have choices. Listening to our customers and providing the opportunity for customers to share their experiences is just one example of why DATATRAK is a preferred provider," claimed Birch.

Join DATATRAK Thought Leaders:

• Twitter
• LinkedIn
• SlideShare
• The DATATRAK Blog

Tweet: #DATATRAK and NTT DATA host first user conference with strong customer confidence http://ow.ly/XUIoF

About DATATRAK
DATATRAK International is a worldwide technology and services company delivering Unified dClinical™ solutions and related services for the clinical trials industry. DATATRAK offers a comprehensive solution on a single, unified platform. The Company delivers a complete portfolio of software products designed to accelerate the collection, analysis and submission of clinical trials. The DATATRAK ONE® software solution, deployed worldwide supports Phase I - Phase IV drug and device studies in multiple languages throughout the world. For more information, visit http://www.datatrak.com.

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company's report filed with the OTCQX Market on March 13, 2015 announcing its results for the full year period ended December 31, 2014. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

CONTACT:
Dorothy Radke
Director Marketing
DATATRAK International, Inc.
+1-440-443-0082

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.